PCRX Earnings & Financial Statements
Pacira BioSciences, Inc.
$36.40
+$0.09(+0.25%)
69
Overall
60
Value
83
Tech
65
Quality
Market Cap
$1.45B
Volume
2.33M
52W Range
$18.80 - $36.46
Target Price
$32.00
PCRX earnings and financial statements: Pacira BioSciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PCRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $726.41M | $700.97M | $657.0K | $666.82M | $541.53M |
| Cost of revenue | $149.75M | $170.43M | $184.67M | $199.29M | $140.25M |
| Operating income | $19.19M | -$73.37M | $87.67M | $60.02M | $89.92M |
| EBITDA | $128.34M | $35.47M | $161.33M | $147.59M | $113.95M |
| Net income | $7.03M | -$99.56M | $41.95M | $15.91M | $41.98M |
| EPS (diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B |
| Total liabilities | $571.81M | $775.17M | $704.26M | $906.19M | $1.34B |
| Shareholders’ equity | $693.11M | $778.35M | $870.13M | $775.01M | $730.41M |
| Cash and equivalents | $158.54M | $276.77M | $153.30M | $104.14M | $585.58M |
| Long-term debt | $408.37M | $428.19M | $568.60M | $720.63M | $746.26M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $151.99M | $189.39M | $154.65M | $145.27M | $125.72M |
| Capital expenditure | -$15.33M | -$10.64M | -$15.16M | -$30.08M | -$45.87M |
| Free cash flow | $136.66M | $178.75M | $139.49M | $115.20M | $79.85M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PCRX | $36.40 | +0.2% | 2.33M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Pacira BioSciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW